{"disease":{"id":"myasthenia-gravis-generalized","name":"myasthenia gravis generalized"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT06617741","title":"Myasthenia Gravis Foundation of America Global MG Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3800,"lead_sponsor_name":"Myasthenia Gravis Foundation of America","has_results":false},{"nct_id":"NCT04115293","title":"Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Ra Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05737160","title":"Study of Telitacicept in Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT03304054","title":"Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Catalyst Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07284420","title":"ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT07294170","title":"ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT05067348","title":"Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT05716035","title":"Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":64,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT06455709","title":"Markers of Favorable Response to Complement Inhibitors Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07072988","title":"Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT07224386","title":"Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"BioSensics","has_results":false},{"nct_id":"NCT06685055","title":"Markers of Favorable Response to FcRn Inhibitors(INFORM)","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06909253","title":"Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02565576","title":"Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05868837","title":"Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07501702","title":"A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT04146051","title":"Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Cartesian Therapeutics","has_results":false},{"nct_id":"NCT05214612","title":"Predictors and Prognostic Factors of Myasthenia Gravis Outcome","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06485232","title":"Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT07226830","title":"Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"BioSensics","has_results":false},{"nct_id":"NCT06958939","title":"The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Ting Chang, MD","has_results":false},{"nct_id":"NCT04431895","title":"Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT03759366","title":"A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}